The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center.
A. M. Molina
Research Funding - Novartis
X. Jia
No relevant relationships to disclose
M. S. Ginsberg
No relevant relationships to disclose
S. Velasco
No relevant relationships to disclose
D. R. Feldman
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
S. Patil
No relevant relationships to disclose
R. J. Motzer
Research Funding - Pfizer